PTGX PE Ratio & Valuation,Is PTGX Overvalued

PTGX Relative Valuation

PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTGX is overvalued; if below, it's undervalued.

Historical Valuation

Protagonist Therapeutics Inc (PTGX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -19.55. The fair price of Protagonist Therapeutics Inc (PTGX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 94.79 USD , Protagonist Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：94.79

Fair

Undervalued

64.86

70.13

EV/EBITDA

Protagonist Therapeutics Inc. (PTGX) has a current EV/EBITDA of 70.13. The 5-year average EV/EBITDA is 19.02. The thresholds are as follows: Strongly Undervalued below -252.52, Undervalued between -252.52 and -116.75, Fairly Valued between 154.79 and -116.75, Overvalued between 154.79 and 290.56, and Strongly Overvalued above 290.56. The current Forward EV/EBITDA of 70.13 falls within the Historic Trend Line -Fairly Valued range.

-88.17

EV/EBIT

Protagonist Therapeutics Inc. (PTGX) has a current EV/EBIT of -88.17. The 5-year average EV/EBIT is -1.12. The thresholds are as follows: Strongly Undervalued below -143.91, Undervalued between -143.91 and -72.51, Fairly Valued between 70.28 and -72.51, Overvalued between 70.28 and 141.67, and Strongly Overvalued above 141.67. The current Forward EV/EBIT of -88.17 falls within the Undervalued range.

25.42

Protagonist Therapeutics Inc. (PTGX) has a current PS of 25.42. The 5-year average PS is 40.91. The thresholds are as follows: Strongly Undervalued below -15.03, Undervalued between -15.03 and 12.94, Fairly Valued between 68.89 and 12.94, Overvalued between 68.89 and 96.86, and Strongly Overvalued above 96.86. The current Forward PS of 25.42 falls within the Historic Trend Line -Fairly Valued range.

28.90

P/OCF

Protagonist Therapeutics Inc. (PTGX) has a current P/OCF of 28.90. The 5-year average P/OCF is 23.63. The thresholds are as follows: Strongly Undervalued below -286.79, Undervalued between -286.79 and -131.58, Fairly Valued between 178.84 and -131.58, Overvalued between 178.84 and 334.05, and Strongly Overvalued above 334.05. The current Forward P/OCF of 28.90 falls within the Historic Trend Line -Fairly Valued range.

40.31

P/FCF

Protagonist Therapeutics Inc. (PTGX) has a current P/FCF of 40.31. The 5-year average P/FCF is 33.02. The thresholds are as follows: Strongly Undervalued below -254.23, Undervalued between -254.23 and -110.60, Fairly Valued between 176.64 and -110.60, Overvalued between 176.64 and 320.27, and Strongly Overvalued above 320.27. The current Forward P/FCF of 40.31 falls within the Historic Trend Line -Fairly Valued range.

Protagonist Therapeutics Inc (PTGX) has a current Price-to-Book (P/B) ratio of 9.17. Compared to its 3-year average P/B ratio of 4.54 , the current P/B ratio is approximately 101.93% higher. Relative to its 5-year average P/B ratio of 4.23, the current P/B ratio is about 116.84% higher. Protagonist Therapeutics Inc (PTGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.03% , the current FCF yield is about -100.00% lower.

9.17

P/B

Median3y

4.54

Median5y

4.23

1.07

FCF Yield

Median3y

-1.35

Median5y

-6.03

Competitors Valuation Multiple

The average P/S ratio for PTGX's competitors is 0.42, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 0.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PTGX increased by 145.57% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 57.92 to 131.63.

The secondary factor is the Margin Expansion, contributed 17.53%to the performance.

Overall, the performance of PTGX in the past 1 year is driven by P/E Change. Which is more unsustainable.

0.79%

4.68M → 4.71M

Revenue Growth

17.53%

-710.37 → -834.87

Margin Expansion

127.25%

57.92 → 131.63

P/E Change

145.57%

38.60 → 94.79

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Protagonist Therapeutics Inc (PTGX) currently overvalued or undervalued?

What is Protagonist Therapeutics Inc (PTGX) fair value?

PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Protagonist Therapeutics Inc (PTGX) is between +Inf to +Inf according to relative valuation methord.

How does PTGX's valuation metrics compare to the industry average?

The average P/S ratio for PTGX's competitors is 0.42, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 0.79%, this premium appears unsustainable.

What is the current P/B ratio for Protagonist Therapeutics Inc (PTGX) as of Dec 16 2025?

As of Dec 16 2025, Protagonist Therapeutics Inc (PTGX) has a P/B ratio of 9.17. This indicates that the market values PTGX at 9.17 times its book value.

What is the current FCF Yield for Protagonist Therapeutics Inc (PTGX) as of Dec 16 2025?

As of Dec 16 2025, Protagonist Therapeutics Inc (PTGX) has a FCF Yield of 0.00%. This means that for every dollar of Protagonist Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Protagonist Therapeutics Inc (PTGX) as of Dec 16 2025?

As of Dec 16 2025, Protagonist Therapeutics Inc (PTGX) has a Forward P/E ratio of 64.86. This means the market is willing to pay $64.86 for every dollar of Protagonist Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Protagonist Therapeutics Inc (PTGX) as of Dec 16 2025?

As of Dec 16 2025, Protagonist Therapeutics Inc (PTGX) has a Forward P/S ratio of 0.00. This means the market is valuing PTGX at $0.00 for every dollar of expected revenue over the next 12 months.

PTGX Valuation